S-100B concentrations predict disease-free survival in stage III melanoma patients

Annals of Surgical Oncology

Volumn 16, Issue 12, 2009, Pages 3455-3462

  Kruijff, S ^a   Bastiaannet, E ^a   Muller Kobold, A C ^a   Van Ginkel, R J ^a   Suurmeijer, A J H ^a   Hoekstra, H J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; PROTEIN S 100;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER SIZE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOENZYME TECHNIQUES; L-LACTATE DEHYDROGENASE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NERVE GROWTH FACTORS; PERIOPERATIVE CARE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; S100 PROTEINS; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 71549127399     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0629-8     Document Type: Article

References (56)

1. S Siesling O Visser JA van Dijck JW Coebergh 2006 Trends in the incidence and death from cancer from 1989-2003 in The Netherlands Ned Tijdschr Geneeskd. 150 2490 2496 1:STN:280:DC%2BD28npvFGjtg%3D%3D 17137098
2. C Garbe TK Eigentler 2007 Diagnosis and treatment of cutaneous melanoma: state of the art 2006 Melanoma Res. 17 117 127 10.1097/CMR.0b013e328042bb36 17496787 (Pubitemid 46673905)
3. AB Francken E Bastiaannet HJ Hoekstra 2005 Follow-up in patients with localised primary cutaneous melanoma Lancet Oncol. 6 608 621 10.1016/S1470-2045(05)70283-7 16054572 (Pubitemid 41051939)
4. DL Morton JF Thompson AJ Cochran N Mozzillo R Elashoff R Essner, et al. 2006 Sentinel-node biopsy or nodal observation in melanoma N Engl J Med. 355 1307 1317 10.1056/NEJMoa060992 1:CAS:528:DC%2BD2sXisVaqtr4%3D 17005948 (Pubitemid 44465459)
5. CM Balch SJ Soong JE Gershenwald JF Thompson DS Reintgen N Cascinelli, et al. 2001 Prognostic factors analysis of 17,600 melanoma patients. Validation of the American Joint Committee on Cancer melanoma system J Clin Oncol. 19 3622 3634 1:STN:280:DC%2BD3MvlvV2ktA%3D%3D 11504744
6. E Bastiaannet WJ Oyen S Meijer OS Hoekstra T Wobbes PL Jager, et al. 2006 Impact of 18F fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients Br J Surg. 93 243 249 10.1002/bjs.5174 1:STN:280:DC%2BD28%2FmsVWiug%3D%3D 16323165 (Pubitemid 43259613)
7. Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, et al. Prospective comparison of FDG-PET and CT in 251 melanoma patients with palpable lymph node metastases; diagnostic accuracy and impact on treatment. J Clin Oncol. (in press).
8. E Bastiaannet OS Hoekstra WJ Oyen PL Jager T Wobbes HJ Hoekstra 2006 Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases Ann Surg Oncol. 13 919 926 10.1245/ASO.2006.02.007 16788752 (Pubitemid 43920923)
9. L Brochez JM Naeyaert 2000 Serological markers for melanoma Br J Dermatol. 143 256 268 10.1046/j.1365-2133.2000.03649.x 1:STN:280: DC%2BD3cvisVGgug%3D%3D 10951131 (Pubitemid 30650391)
10. SJ Finck AE Giuliano DL Morton 1983 LDH and melanoma Cancer. 51 840 843 10.1002/1097-0142(19830301)51:5<840::AID-CNCR2820510516>3.0.CO;2-7 1:STN:280:DyaL3s7gt1OqtA%3D%3D 6821850
11. CP Karakousis CM Balch MM Urist MM Ross TJ Smith AA Bartolucci 1996 Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial Ann Surg Oncol. 3 446 452 10.1007/BF02305762 1:STN:280:DyaK2s%2FjtV2mug%3D%3D 8876886
12. MN Sirott DF Bajorin GY Wong Y Tao PB Chapman MA Templeton, et al. 1993 Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis Cancer. 72 3091 3098 10.1002/1097-0142(19931115)72: 10<3091::AID-CNCR2820721034>3.0.CO;2-V 1:STN:280:DyaK2c%2Fjs1Oisg%3D%3D 8221576 (Pubitemid 23335058)
13. OC Fagnart CJ Sindic C Laterre 1988 Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system Clin Chem. 34 1387 1391 1:CAS:528:DyaL1cXlsVGlurk%3D 3292082
14. HB Guo B Stoffel-Wagner T Bierwirth J Mezger D Klingmüller 1995 Clinical significance of serum S100 in metastatic malignant melanoma Eur J Cancer. 31A 924 928 10.1016/0959-8049(95)00087-9 1:STN:280:DyaK2MznsVyhug%3D%3D 7646923
15. LH Smit CM Korse AA Hart JM Bonfrer JB Haanen JM Kerst, et al. 2005 Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients Eur J Cancer. 41 386 392 10.1016/j.ejca.2004.10.019 1:CAS:528:DC%2BD2MXhtVGqtLs%3D 15691637 (Pubitemid 40187209)
16. A Jackel M Deichmann V Waldmann M Bock H Näher 1999 S-100 beta protein in serum, a tumor marker in malignant melanoma-current state of knowledge and clinical experience Hautarzt. 50 250 256 10.1007/s001050050897 1:STN:280:DyaK1M3otlensQ%3D%3D 10354916 (Pubitemid 29200322)
17. E Bastiaannet JC Beukema HJ Hoekstra 2005 Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications Cancer Treat Rev. 31 18 26 10.1016/j.ctrv.2004.09.005 1:STN:280: DC%2BD2M%2FnvVOgtA%3D%3D 15707701 (Pubitemid 40246987)
18. Henderson MA, Burmeister B, Thompson JF, Di Iulio J,Fisher R, Hong A, et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial. 2009 ASCO Annual meeting, J Clin Oncol. 2009;27 Supplement: Abstract No. LBA9084.
19. G Ghanem B Loir R Morandini F Sales D Lienard A Eggermont, et al. 2001 On the release and half life of S100B protein in the peripheral blood of melanoma patients Int J Cancer. 94 586 590 10.1002/ijc.1504 1:CAS:528: DC%2BD3MXns1Gnu78%3D 11745448 (Pubitemid 32979553)
20. ED Martenson LO Hansson B Nilsson E von Schoultz E Månsson Brahme U Ringborg, et al. 2001 Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma J Clin Oncol. 19 824 831 1:CAS:528:DC%2BD3MXhtlGrt7s%3D 11157036
21. MQ Mohammed HD Abraha RA Sherwood K MacRae S Retsas 2001 Serum S100beta protein as a marker of disease activity in patients with malignant melanoma Med Oncol. 18 109 120 10.1385/MO:18:2:109 1:CAS:528:DC%2BD3MXptVCjtb4%3D 11778756 (Pubitemid 32929483)
22. BJ Curry M Farrelly P Hersey 1999 Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma Melanoma Res. 9 557 567 1:CAS:528:DC%2BD3cXjsVWlsg%3D%3D 10661766
23. JM Bonfrer CM Korse OE Nieweg EM Rankin 1998 The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma Br J Cancer. 77 2210 2214 1:CAS:528:DyaK1cXktlCmtLk%3D 9649135
24. J Buer M Probst A Franzke S Duensing J Haindl M Volkenandt, et al. 1997 Elevated serum levels of S100 and survival in metastatic malignant melanoma Br J Cancer. 75 1373 1376 1:STN:280:DyaK2s3pvF2isA%3D%3D 9155061
25. LO Hansson SE von E Djureen J Hansson B Nilsson U Ringborg 1997 Prognostic value of serum analyses of S-100 protein beta in malignant melanoma Anticancer Res. 17 3071 3073 1:STN:280:DyaK2svntVWrtQ%3D%3D 9329604
26. JM Bonfrer CM Korse SP Israels 1997 Serum S-100 has prognostic significance in malignant melanoma Anticancer Res. 17 2975 2977 1:STN:280:DyaK2svntVWlsA%3D%3D 9329579
27. AP Hamberg CM Korse JM Bonfrer GC de Gast 2003 Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma Melanoma Res. 13 45 49 10.1097/00008390-200302000-00008 1:CAS:528:DC%2BD3sXptFOhtg%3D%3D 12569284 (Pubitemid 36269813)
28. A Hauschild G Engel W Brenner R Gläser H Mönig E Henze, et al. 1999 Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy Br J Dermatol. 140 1065 1071 10.1046/j.1365-2133.1999.02905.x 1:CAS:528:DyaK1MXksVaqsrw%3D 10354072 (Pubitemid 29284578)
29. G Henze R Dummer HI Joller-Jemelka R Böni G Burg 1997 Serum S100-a marker for disease monitoring in metastatic melanoma Dermatology. 194 208 212 10.1159/000246103 1:STN:280:DyaK2szjtFGjsA%3D%3D 9187834
30. T Banfalvi M Boldizsar M Gergye K Gilde T Kremmer S Otto 2002 Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma Pathol Oncol Res. 8 183 187 10.1007/BF03032392 12515998
31. T Banfalvi K Gilde M Gergye M Boldizsar T Kremmer S Otto 2003 Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma Eur J Cancer. 39 164 169 10.1016/S0959-8049(02)00487-2 1:CAS:528:DC%2BD38XpvVWnt7Y%3D 12509947 (Pubitemid 36057065)
32. C Garbe U Leiter U Ellwanger HJ Blaheta F Meier G Rassner, et al. 2003 Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients Cancer. 97 1737 1745 10.1002/cncr.11250 1:CAS:528:DC%2BD3sXivFeitbg%3D 12655531 (Pubitemid 36350717)
33. J Domingo-Domenech T Castel JM Auge XA Garcia-Albeniz C Conill S Puig, et al. 2007 Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients Tumour Biol. 28 264 272 10.1159/000110424 1:CAS:528:DC%2BD2sXhtlCgsbnL 17962723 (Pubitemid 350165832)
34. LH Smit OE Nieweg CM Korse JM Bonfrer BB Kroon 2005 Significance of serum S-100B in melanoma patients before and after sentinel node biopsy J Surg Oncol. 90 66 69 10.1002/jso.20238 1:CAS:528:DC%2BD2MXks1ajt7g%3D 15844182 (Pubitemid 40594102)
35. YS Chun Y Wang DY Wang DM McClain A Lucci PF Mansfield, et al. 2008 S100B levels are more accurate than LDH levels at predicting survival in melanoma patients Ann Surg Oncol 15 96 10.1245/s10434-007-9631-1 (P211)
36. S Mocellin G Zavagno D Nitti 2008 The prognostic value of serum S100B in patients with cutaneous melanoma: A meta-analysis Int J Cancer. 123 2370 2376 10.1002/ijc.23794 1:CAS:528:DC%2BD1cXhtleiurbP 18752249
37. AA Tarhini J Stuckert S Lee C Sander JM Kirkwood 2009 Prognostic significance of serum S100B surgically resected melanoma Patients Participating in Intergroup Trial ECOG 1694 J Clin Oncol. 27 38 44 10.1200/JCO.2008.17.1777 19047287
38. G Miliotes GH Lyman CW Cruse C Puleo PA Albertini D Rapaport, et al. 1996 Evaluation of new putative tumor markers for melanoma Ann Surg Oncol. 3 558 563 10.1007/BF02306089 1:STN:280:DyaK2s%2Fnt1OhsQ%3D%3D 8915488
39. HD Abraha LC Fuller AW Du Vivier EM Higgins RA Sherwood 1997 Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma Br J Dermatol. 137 381 385 10.1111/j.1365-2133.1997.tb03742.x 1:CAS:528: DyaK2sXmslyitL8%3D 9349333
40. AK Bosserhoff M Kaufmann B Kaluza I Bartke H Zirngibl R Hein, et al. 1997 Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma Cancer Res. 57 3149 3153 1:CAS:528:DyaK2sXkvFKqsro%3D 9242442
41. A Tofani RP Cioffi R Sciuto S Rea A Festa F Di Filippo, et al. 1997 S-100 and NSE as serum markers in melanoma Acta Oncol. 36 761 764 10.3109/02841869709001351 1:STN:280:DyaK1c7ktFSqtA%3D%3D 9490097
42. ES Schultz TL Diepgen DP Von Den 1998 Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma Br J Dermatol. 138 426 430 10.1046/j.1365-2133.1998.02119.x 1:STN:280:DyaK1c3ktFyqtw%3D%3D 9580794 (Pubitemid 28145509)
43. JM Bonfrer CM Korse 2001 Monitoring malignant melanoma with the S-100B tumour marker Recent Results Cancer Res. 158 149 157 1:CAS:528: DC%2BD3cXot1aitLc%3D 11092042
44. E Seregni S Massaron A Martinetti MT Illeni D Rovini F Belli, et al. 1998 S100 protein serum levels in cutaneous malignant melanoma Oncol Rep. 5 601 604 1:STN:280:DyaK1c3gslWhtQ%3D%3D 9538159
45. A Hauschild G Engel W Brenner R Gläser H Mönig E Henze, et al. 1999 S100B protein detection in serum is a significant prognostic factor in metastatic melanoma Oncology. 56 338 344 10.1159/000011989 1:CAS:528: DyaK1MXjsFWktr0%3D 10343200 (Pubitemid 29240361)
46. C Berking EM Schlupen A Schrader J Atzpodien M Volkenandt 1999 Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmunometric assay for S-100 Arch Dermatol Res. 291 479 484 10.1007/s004030050441 1:CAS:528:DyaK1MXnsFSksr4%3D 10541877 (Pubitemid 29484127)
47. P Kaskel C Berking S Sander M Volkenandt RU Peter G Krähn 1999 S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma J Am Acad Dermatol. 41 962 969 10.1016/S0190-9622(99)70254-9 1:STN:280:DC%2BD3c%2FktVegtg%3D%3D 10570381
48. M Brouard V Quillien I Ollivier T Lesimple H Adamski J Chevrant-Breton 2000 Serum S100B protein and stage of cutaneous melanoma: a prospective study Ann Dermatol Venereol. 127 56 59 1:STN:280:DC%2BD3c7otlartQ%3D%3D 10717564
49. MS Vuoristo P Kellokumpu-Lehtinen S Laine LM Parvinen M Hahka-Kemppinen M Korpela, et al. 2000 The value of serum S-100beta and interleukins as tumour markers in advanced melanoma Melanoma Res. 10 237 241 1:CAS:528: DC%2BD3cXltV2rsro%3D 10890377
50. CS Jury EJ McAllister RM MacKie 2000 Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma Br J Dermatol. 143 269 274 10.1046/j.1365-2133.2000.03650.x 1:CAS:528:DC%2BD3cXmsF2nsbc%3D 10951132 (Pubitemid 30650392)
51. A Juergensen U Holzapfel R Hein W Stolz R Buettner A Bosserhoff 2001 Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta Tumour Biol. 22 54 58 10.1159/000030147 1:CAS:528:DC%2BD3cXos1Omurk%3D 11054027
52. V Rebmann S Ugurel W Tilgen U Reinhold H Grosse-Wilde 2002 Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients Int J Cancer. 100 580 585 10.1002/ijc.10524 1:CAS:528:DC%2BD38Xlslyjtr4%3D 12124808 (Pubitemid 34816159)
53. R Andres JI Mayordomo P Zaballos J Rodino D Isla P Escudero, et al. 2004 Prognostic value of serum S-100B in malignant melanoma Tumori. 90 607 610 1:CAS:528:DC%2BD2MXitlWjsLg%3D 15762365
54. S Ugurel 2005 Serum markers for melanoma Hautarzt. 56 173 184 10.1007/s00105-004-0893-2 1:STN:280:DC%2BD2M%2FotFKkug%3D%3D 15657726 (Pubitemid 40568374)
55. H Schmidt BS Sorensen K Fode E Nexo H von der Maase 2005 Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy Melanoma Res. 15 409 416 10.1097/00008390-200510000-00009 1:CAS:528:DC%2BD2MXhtVantb3E 16179868 (Pubitemid 41558951)
56. MG Cao JM Auge R Molina R Marti C Carrera T Castel, et al. 2007 Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma Anticancer Res. 27 595 599 1:CAS:528:DC%2BD2sXjs12msrk%3D 17348447